Imagen de Portada

Real‐World Persistence and Characteristics of Type 2 Diabetes Patients Prescribed Semaglutide in Scotland

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	David Alexander Dickie, Ramil Burden, Alexander C. Miller, Lucy Mackillop, Kevin Heath, Sumit Dutta, Jesse Dawson
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Journal of Diabetes
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study
por: Taweesak Wannachalee, et al.
Publicado: (2026)

Long‐Term Effectiveness of Once‐Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real‐World Study
por: Benedetta Maria Bonora, et al.
Publicado: (2025)

Real‐World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non‐Diabetic Adults
por: Mai Katsura, et al.
Publicado: (2026)

Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III , Active‐Controlled Study
por: Unnikrishnan Ambika Gopalakrishnan, et al.
Publicado: (2026)

Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis
por: Ali Abdullah, et al.
Publicado: (2025)

A Multicentre, Prospective, Non‐Interventional Single‐Arm Study Investigating the Impact of Once‐Daily Oral Semaglutide in a Real‐World Adult Population With Type 2 Diabetes in Mexico
por: Guillermo González‐Gálvez, et al.
Publicado: (2026)

Patient Characteristics Associated With Annual Nutrition Visits in Children With Type 1 Diabetes
por: Svetlana Azova, et al.
Publicado: (2025)

Identifying Provider Prescribing Practices for GLP‐1RAs and SGLT‐2is in Patients With Type 2 Diabetes to Address Pharmacoinequity
por: Parnnate Wongsirisakul, et al.
Publicado: (2026)

Comment on ‘Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World ( STEER )’
por: Chih‐Yuan Wang
Publicado: (2026)

Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study
por: Assaf Issachar, et al.
Publicado: (2026)

Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach
por: Rune Viig Overgaard, et al.
Publicado: (2026)

Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials
por: Francesco Zaccardi, et al.
Publicado: (2026)

Cardiovascular Outcomes With SGLT‐2 Inhibitors in Patients With Type 2 Diabetes and Obstructive Sleep Apnoea: A Real‐World Analysis
por: Reuben L. Odai, et al.
Publicado: (2026)

SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials
por: Pierre Bel Lassen, et al.
Publicado: (2026)

Real‐World Insights Into Hypoglycemia Risk While Driving in Teens and Young Adults With Type 1 Diabetes
por: Kalyan Pamidimukkala, et al.
Publicado: (2025)

Equity of Continuous Glucose Monitoring in Children and Young People With Type 1 Diabetes: A Systematic Review
por: James Howard Dicks, et al.
Publicado: (2025)

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study
por: Michael G. Nanna, et al.
Publicado: (2026)

Impact of Albuminuria and Renal Dysfunction on the Anemia‐Improving Effect of SGLT2 Inhibitors in Patients With Type 2 Diabetes: A Real‐World Observational Study
por: Ayami Kajiwara-Morita, et al.
Publicado: (2025)

Effectiveness and Safety of Finerenone in Patients With Diabetic Kidney Disease: A Real‐World Observational Study
por: Jaehyun Bae, et al.
Publicado: (2026)

A Qualitative Analysis of Provider‐Level Barriers to Prescribing Diabetes Technology
por: Jennifer Maizel, et al.
Publicado: (2025)

SGLT2 Inhibitors and the Risk of Infections in Type 2 Diabetes: Systematic Review and Meta‐Analyses of Real‐World Evidence
por: Maria J. Alfonso Arvez, et al.
Publicado: (2025)

Association of Different Types of Diabetic Autonomic Neuropathy With Left Ventricular Diastolic Dysfunction in Patients With Type 2 Diabetes: A Cross‐Sectional Study
por: Ruixue Feng, et al.
Publicado: (2025)

Usefulness of Once‐Weekly GLP‐1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study
por: Tomohiko Kimura, et al.
Publicado: (2024)

The Diabetic Cognitive Impairment Score for Early Screening of Cognitive Impairment in Type 2 Diabetes Patients
por: Shujun Zhang, et al.
Publicado: (2025)

Exploring the Glycemic Control of Pay‐for‐Performance Program for Psychiatric Patients With Diabetes in Real World: A Retrospective Quasiexperimental Study
por: Chin-Chou Yang, et al.
Publicado: (2025)

Clinical and Pathological Characteristics and Prognosis of Diabetic Nephropathy Patients With Tertiary Lymphoid Structures
por: Yongjie Zhuo, et al.
Publicado: (2025)

Real‐World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido‐ TZP Study
por: Fumika Maruyama, et al.
Publicado: (2026)

Understanding Patient Perceptions of Genetic Testing to Predict Type 2 Diabetes Risk After Gestational Diabetes
por: Ria Patel, et al.
Publicado: (2026)

Age Characteristics of Patients With Type 2 Diabetic Foot Ulcers and Predictive Risk Factors for Lower Limb Amputation: A Population‐Based Retrospective Study
por: Yuanying Yao, et al.
Publicado: (2024)

Interpreting Post‐Discontinuation Trajectories After Semaglutide or Tirzepatide
por: Man Sun, et al.
Publicado: (2026)

Long‐Term Effects of Intensive Lifestyle Intervention on Cardiometabolic Outcomes in Patients With Diabetes in Real‐World Clinical Practice: A 15‐Year Longitudinal Study
por: Abdelrahman Khater, et al.
Publicado: (2025)

Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis
por: Jan Oscarsson, et al.
Publicado: (2026)

Comparison of Cognitive Abilities, Depression and Anxiety of Type II Diabetic Patients with Healthy Individuals in Isfahan Province in 2015
por: Fatemeh‎ Solimany
Publicado: (2018)

SemaGBA : A System Dynamics Model of the Semaglutide‐Responsive Gut‐Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight
por: Vivan C. W. Kennis, et al.
Publicado: (2026)

Counseling Preferences Among Patients With Type 2 Diabetes: Implications for Personalized Care
por: Thao Ngoc Phuong Nguyen, et al.
Publicado: (2025)

QTc Interval and Its Associated Factors in Patient With Type 2 Diabetic Mellites
por: Deresse Sinamaw Asmare, et al.
Publicado: (2025)

Semaglutide and MASH resolution: A pooled analysis of recent trials
por: Alaa Abdrabou Abouelmagd, et al.
Publicado: (2025)

Increased Urinary Extracellular Vesicles and Reduced Expression of NEDD4L in Patients With Type 2 Diabetes and Diabetic Nephropathy
por: Nikhil Thyagarajan, et al.
Publicado: (2026)

Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status
por: Franziska S. Ulrich, et al.
Publicado: (2026)

Association of Monocyte‐to‐HDL Cholesterol Ratio with Endothelial Dysfunction in Patients with Type 2 Diabetes
por: Huihui Zhang, et al.
Publicado: (2024)